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THE EFFECT OF ALOE VERA, VITAMIN C AND E ON TUMOUR 
MARKER ENZYMES IN HEPATOCARCINOGENESIS. 
By 
ABDAH MD. AKIM 
February 1998 
Chairman: Associate Professor Nor Aripin Shamaan, Ph.D. 
Faculty: Science and Environmental Studies 
The effects of Aloe vera (A V), vitamin C (VC), alpha-tocopherol (T) and 
gamma-tocotrienol (E) on the activities of six tumour marker enzymes; alkaline 
phosphatase (ALP), glutathione-S-transferase (GST), gamma-glutamyl transferase 
(GGT), glutathione peroxidase (GPx), glutathione reductase (GRx) and uridyl 
diphosphoglucuronyl transferase (UDPGT) in rat liver carcinogenesis were studied. 
Liver cancer was induced by diethylnitrosamine (DEN) and 2 -acetylaminofluorene 
(AAF) followed by partial hepatectomy. Ninety male rats (Rattus norwegicus, 120-
150g, 6-7 weeks old) were divided into 15 groups. Six groups comprised the normal 
and supplemented-control groups. Hepatocarcinogenesis was induced in the other 
nine groups. Four groups were supplemented with A V, VC, E and T respectively 
and the other 4 groups were given TNC, T/AV, ENC and E/AV respectively. The 
last group remained as the cancer-control group. 
Xl 
Aloe vera and vitamin C were administered ad libitum at doses of 0. 1 mg/L 
water and 41 .7 mg/L water respectively, in both control and cancer groups. Alpha­
tocopherol and gamma-tocotrienol were administered at a dose of 34 mglkg diet and 
30 mglkg diet, respectively. The rats were sacrificed by cervical dislocation after 16 
weeks. 
An increase (p<0.05) in all six tumour marker enzymes was observed in the 
cancer-treated group compared to the normal-control group. Aloe vera 
supplementation significantly (p<0.05) decreased the tumour marker enzyme 
activities in cancer-induced liver compared to the cancer-control group. Gamma­
tocotrienol exerted a better effect than alpha-tocopherol in reducing the enzyme 
activities in cancer-induced liver. Vitamin C significantly (p<0.05) decreased the 
enzyme activities in GPx, GRx, GST and UDPGT. However, non of the 
supplementations decreased the alkaline phosphatase activity in the liver cancer. 
In the four cancer-induced groups that received combined supplementation, 
the tumour enzyme marker activities were greatly reduced (p<0.05) compared to the 
single supplementation. A combined supplementation of alpha-tocopherol and 
vitamin C gave the best result compared to other combinations. 
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Fakulti: Sains dan Pengajian Alam Sekitar 
Kesan Aloe vera (A V), vitamin C (VC), alfa-tokoferol (T) dan gama-
tokotrienol (E) ke atas aktiviti enzim penanda tumor; alkaline fosfatase (ALP), 
glutation-S-transferase (GS T), gama-glutamiltransferase (GG T), glutation perosidase 
(GPx), glutation reduktase (GRx) dan uridil difosfoglukuronil transferase (UDPGT) 
di dalam tikus teraruh hepatokarsinogenesis telah dikaji. Aruhan kanser ialah 
melalui pemberian dietilnitrosamina (DEN) dan 0.02% 2-asetilaminofluorena (AAF) 
diikuti hepatektomi separa. 90 tikus albino jantan (Rattus nowegicus, 120-150g, 
berusia 6-7 minggu) telah dibahagikan kepada 1 5  kumpulan. 6 kumpulan adalah 
untuk kawalan normal. Hepatokarsinogenesis telah diaruh di dalam 9 kumpulan di 
mana 4 kumpulan diberi AV, VC, E dan T dan 4 kumpulan lagi diberi TNC, T/AV, 
ENC dan E/AV. Kumpulan terakhir adalah kawalan kanser. Aloe vera dan vitamin 
xiii 
C diberi dengan dos 0.1 mg/L air dan 41.7 mg/L air secara ad libitum. Alfa­
tokoferol dan gama-tokotrienol diberi pada dos 34 mglkg diet dan 30 mglkg diet. 
Semua tikus dibunuh secara dislokasi servikal selepas 16  minggu. 
Kesemua aktiviti penanda tumor enzim didapati meningkat (p<O.05) pada 
hepar kanser berbanding dengan kumpulan kawalan. Pada hepar kanser, Aloe vera 
didapati mengur�gkan dengan signiftkan (p<0.05) semua aktiviti enzim kecuali 
aktiviti alkalin fosfatase. Gama-tokotrienol menunjukkan kesan yang lebih ketara 
daripada alfa-tokoferol dalam mengurangkan aktiviti enzim pada hepar kanser. 
Vitamin C mengurangkan (p<O.05) aktiviti enzim GPx, GRx, GST dan UDPGT. 
Kesemua empat kumpulan yang menerima suplementasi berkombinasi 
mengurangkan (p<O.05) semua aktiviti enzim dengan lebih ketara berbanding dengan 
kumpulan yang menerima hanya suplementasi tunggal. Kombinasi alfa-tokoferol 
dan vitamin C memberi kesan perlindungan yang paling baik berbanding dengan 
kombinasi lain. 
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CHAPTERl 
INTRODUCTION 
In some parts of the world especially tropical Africa and parts of Asia, 
primary cancer of the liver is one of the commonest forms of malignant tumour. In 
the Western world, alcohol is the most recognised cause whereas in Asia, the 
possible role of chemical carcinogens such as aflatoxin has been identified (Alfm­
Slater and Kritchevsky, 1991). Diagnosis is difficult since there is no specific 
symptoms; in all cases, there is enlargement of the liver. Chemotherapy and 
radiotherapy has little effect to help alleviate the situation and removal of the 
affected part of the liver may be feasible. 
As the familiar proverb "prevention is better than cure", the prevention of this 
disease is obviously the aim of all those who are concerned with health. A number 
of studies had been done on various putative anticarcinogenic substances, including 
the supplementation used in this study; Aloe vera, vitamin C, a-tocopherol and y­
tocotrienol. 
Aloe vera, which is commercially used in skin care product, has only been 
tested recently for its anticarcinogenic properties. Although vitamin C has been long 
known to be a potential anticarcinogen, it gains less interest in this 
2 
subject because it is more commonly used in preventing scurvy and cold. The effect 
of two types of vitamin E; a-tocopherol and y-tocotrienol, which are purified from 
palm oil, on liver cancer had been extensively studied where y-tocotrienol possesses 
a higher anti-cancer property than a-tocopherol (Ong et aI, 1994). There had been 
individual studies on the effect of each supplementation previously (Beattie and 
Sherlocks, 1976). Therefore, this study aims to examine the simultaneous effect of 
the supplementations. 
Measuring the known tumour marker enzymes; alkaline phosphatase (ALP), 
uridyl diphosphoglucuronyl transferase (UDPGT), gamma glutamyl transferase 
(GGT), glutathione-S-transferase (GST), glutathione reductase (GRx) and 
glutathione peroxidase (GPx) will obviate the effect of these supplementations. Each 
tumour marker enzyme used was known to increase its activity in cancer-induced 
liver. However, liver ALP is not being used as extensively as the plasma ALP in 
detecting cancer whereas GST and GGT are now the most used as markers. GPx and 
GRx are involved in the glutathione redox cycle, which is the major endogenous 
protective system against radical species. 
Details on liver cancer, possible anticarcinogenic properties of Aloe vera, 
vitamin C, a-tocopherol and y-tocotrienol and the tumour marker enzymes were 
introduced in the literature review.. The hypotheses that vitamin C and E act as 
anticarcinogens via their antioxidant properties with the elevation of the tumour 
marker enzymes was tested. Therefore, the objective of this research was to evaluate 
the activities of the tumour marker enzymes in Aloe vera, vitamin C, a-tocopherol 
and y-tocotrienol-supplemented as well as their combination in liver cancer. 
CHAPTER 2 
LITERATURE REVIEW 
Cancer in General. 
Cancer may be considered as an alteration of the control mechanisms 
involved in cell division and differentiation. It is a multi-step process which involves 
chemical modification of cellular or genomic DNA (Arcos et ai, 1961). Once 
modified, the affected DNA is replicated and transcribed differently from the normal 
DNA. This hereditary transmittable modification (from neoplastic cells to daughter 
cells) leads to a permanent and anarchic mUltiplication of transformed cells which 
may be different from that of the normal cells. The carcinogenic process may be 
initiated by several agents called initiators. Once carcinogenesis is initiated; the 
second step, termed "promotion", may continue and fmally the third stage of the 
process, called "progression", occurs. Carcinogens may act as initiators, promoters 
or a combination of both (Boyland and Sydnor, 1963). 
Liver Cancer. 
Hepatocellular carcinoma is a common cancer in sub-Saharan Africa and 
parts of Southeast Asia where liver cancer may account for 5-8% of all 
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deaths. The risk of getting hepatoma is high in Asia and is more common in men 
compared to women (Laidlaw and Swendseid, 1991). Liver cancer is rare in western 
countries where it accounts for only 2% of cancer cases in the United States annually. 
The first type ofliver cancer is primary liver cancer. Secondary cancer occurs 
when the liver becomes the seat of secondary deposits of cancers arising primarily in 
other organs. Metastases in the liver often lead to enlargement of the organ with 
discomfort or pain below the ribs on the right and in the flank. There may be 
jaundice arising from interference with the drainage of bile. Other symptoms of liver 
disease such as irritation of the skin, twitching and drowsiness could be detected 
(Scott, 1 979). 
Two forms of liver cancer have been distinguished. The first form is called 
hepatoma, which originates in the cells of the liver cortex and forms ninety percent of 
primary liver cancer. The second is cholangiomas, which line the hepatic ducts that 
drain the bile from the liver and forms 5-10 percent of liver cancer (Manahan, 1989). 
Rapid enlargement of the liver can also be diagnosed as cancer, though not 
necessarily so. Others are pains under the ribs on the right side, loss of weight and 
jaundice. Biopsy of the liver will confirm the precise diagnosis. Treatment such as 
chemotherapy and radiotherapy is of little help and at present, liver transplantation 
has been successful and considered as one of the best treatment available. 
Causes of Liver Cancer. 
The reason for the frequent occurrence of liver cancer is because the liver is 
often the main target for chemically induced toxicities by carcinogens. Its 
susceptibility may be due to several factors; firstly, the liver is the primary site for 
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biotransformation of xenobiotics. Secondly, the liver is the fIrst major site of 
metabolism for carcinogens absorbed from the gastrointestinal tract, which is the 
major route of absorption for most xenobiotics (Boyland and Sydnor, 1963). 
Furthermore, the liver is strategically located between the intestinal tract and 
the general circulation . Through the portal vein, the liver receives a large volume of 
venous blood from the digestive tract while it drains blood through the hepatic veins. 
Compounds absorbed from the intestines, including products of digestion as well as 
toxicants pass through the liver to be metabolised. This renders it to be particularly 
vulnerable to the toxic effects of metabolites (Hodgson and Levi, 1994). Specific 
hepatocarcinogens that have been identified are alcohol, safrol, pyrrolizidine 
alkaloids, cycasin, aflatoxin and several steroid hormones. 
Cancer is the second leading cause of death after heart disease. From 
epidemiological studies, about 35% of cancer is related to diet (Table 1 ,  Hodgson and 
Levi, 1994). The diet probably accounts directly for liver cancer . Carcinogens, both 
natural and synthetic may affect hormone levels, causing other cancers, e.g., 
chemicals in food components that alter oestrogen level in the breast and 
endometrium may cause breast and uterine cancer whereas alteration in testosterone 
level can cause prostate cancer. 
Although the effect of dietary protein on hepatic tumour development has 
been shown in several animal models (Emmelot and Muhlbock, 1964), no human 
epidemiological studies has shown the associations between protein intake and liver 
cancer. The hypothesis that liver cancer was related directly to kwashiorkor (protein­
calorie malnutrition) has now been discarded since the discovery of aflatoxin in 
contaminated foods in Africa and Asia. Although aflatoxin ingestion has been 
correlated closely with liver cancer (Alfm-Slater and Kritchevsky, 1991), the 
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hepatitis B virus also appears to be an important cofactor with carriers having a 200-
fold higher risk compared to non-carriers in Taiwan (Becker, 1975). Prevention is 
possible through a reduction or elimination of aflatoxin in the diet and vaccination 
against the hepatitis B virus; now being undertaken in Gambia (Brennan, 1977). 
Table 1 Causes of Cancer. 
Factors involved in cancer 
Major Factors Best Estimates 
Diet 35% 
Tobacco 30% 
Reproductive and sexual behavior 7% 
Viruses 5% 
Occupation 4% 
Geophysical Factors 3 % 
Alcohol 3% 
Pollution 2% 
Food Additives 1 % 
Medicines 1 % 
Industrial Products 1 % 
Unknown ? 
(Source taken from Hodgson and Levi, 1 994). 
The major factor in liver cancer in North America and Europe appears to be 
caused by excessive alcohol ingestion (Greenberg and Harper, 1960). A threshold 
effect has been suggested where liver cancer occurs only when the level of ingestion 
is sufficient to cause alcoholic hepatitis and consequent cirrhosis (Harris, 1991). It 
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could be concluded that exceSSIve alcohol consumption is the major factor ill 
Western countries and North America for cancer of the liver. 
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Figure 1 Pathway of carcinogen leading to cancer. 
(Source taken from Hodgson and Levi, 1994). 
Multistage Carcinogenesis. 
From animal and human studies, it is clear that carcinogenesis is a multistage 
process (Harris, 1 991) .  Carcinogenesis can be divided into at least three stages 
termed initiation, promotion and progression (Figure 2). Generally, it is thought that 
initiation is a genotoxic event, one in which the primary sequence of DNA is altered 
while promotion is considered a non-genotoxic or epigenetic event (Dragan and Pitot, 
1 992). 
Initiation involves the exposure of normal cells to chemical or physical 
carcinogens, which results in a permanent heritable change in the cell's genome. The 
affected cell is called the initiated cell . The initiated cell may have a decreased 
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response to the inter- and intracellular signals that maintain normal tissue architecture 
and homeostatic growth (Harris, 1991). The initiated cells may remain dormant until 
exposed to a tumour promoter. 
Tumour promotion results m the proliferation of initiated cells and 
enhancement of genetic damage. The development of malignancy from a benign 
tumour encompasses the third step of carcinogenesis termed progression. It involves 
the survival and proliferation of cancer cells and the process of maintenance and 
evolution of malignancy. 
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t 
MUTATED CELL �PROMOTERS weeks months PROMOTION years 
+ TRANSFORMED CELL 
I t 
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l � 
years 
TUMOUR 
Figure 2 Multistage of cancer . (Source taken from Voiculet et aI, 1991) .  
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Carcinogen Metabolism. 
Electrophilic Theory 
In the metabolism of chemical carcinogens, the electrophilic theory states that 
carcinogens are metabolically activated to electrophilic metabolites that are capable 
of interacting with nucleophilic sites in DNA, RNA and protein (Iversen, 1 988). 
Most of the chemical carcinogens are electrophilic reactants. The formation of 
electrophiles generally involves a two-electron oxidation to a carbonium ion 
catalysed by a cytochrome P 450-dependent mixed function oxidase. Most of the 
radicals formed probably do not react with DNA. There are also compounds which 
do not form electrophiles but undergo biotransformation and produce neoplasm, for 
example saccharin and nitrilotriacetic acid. From this observation, two classes of 
chemical carcinogens are distinguishable; genotoxic and epigenetic compounds 
(Iversen, 1988). 
Classes of Chemical Carcinogens. 
Chemical carcinogens can be divided into two major categories; genotoxic 
agents which produce alterations in the genetic material of the host (e.g. DEN) and 
epigenetic (nongenotoxic) agents which do not alter the primary sequence of DNA 
(for e.g. saccharin). The genotoxic agents possess initiator activity whereas the 
epigenetic compounds possess promoter activity (Hodgson and Levi, 1994). 
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Genotoxic agents are further sub-divided into four categories (Iversen, 1988): 
Direct-acting carcinogens which do not require metabolic activation to interact with 
DNA (e.g. beta propiolactone). 
Indirect-acting carcinogens which require metabolic activation (e.g. DEN). 
Radiation which directly ionise DNA. 
Inorganic agents such as arsenic which interfere with the enzymes associated with 
DNA replication. 
Terms in Metabolic Activation. 
The terms parent, proximate and ultimate carcmogen were developed to 
differentiate the action of carcinogens. A parent carcinogen is a compound that must 
be metabolised in order to have carcinogenic activity. A proximate carcinogen is an 
intermediate metabolite requiring further metabolism steps resulting in the ultimate 
carcinogen which is the actual metabolite that covalently binds to the DNA 
(Nakahara et ai, 1 972). Diethylnitrosamine (DEN) and 2-Acetylaminofluorene (2-
AAF) are examples of chemical carcinogens that require metabolic activation before 
they exert their effect. After metabolic activation, both DEN and 2-AAF bind to 
DNA to form DNA adducts. It is further suggested that if the DNA adduct is not 
repaired before the cell replicates, a mutation may be permanent in the daughter cell 
(Emmelot and Muhlbock, 1 964). 
